[ORGANIZATION]
daraksonrasib
Featured in 1 tracked story · first seen
Situations
FDA approves Rasonque for advanced pancreatic cancer
34 clusters · 274 sources · last updated
Latest: FDA approves daraxonrasib for metastatic pancreatic cancer
On 26 August 2026, the U.S. Food and Drug Administration (FDA) granted expedited approval to daraxonrasib, marketed under the brand name Rasonque, for treating adults with metastatic pancreatic ductal adenocarcinoma (PDA